Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.

Abstract

We have previously shown that chronic administration of the selective A3 receptor agonist N6-(3-iodobenzyl)-5'-N-methylcarboxoamidoadenosine (IB-MECA) leads to a significant improvement of postocclusive cerebral blood flow, and protects against neuronal damage and mortality induced by severe forebrain ischemia in gerbils. Using immunocytochemical methods we now show that chronic with IB-MECA results in a significant preservation of ischemia-sensitive microtubule associated protein 2 (MAP-2), enhancement of the expression of glial fibrillary acidic protein (GFAP), and a very intense depression of nitric oxide synthase in the brain of postischemic gerbils. These changes demonstrate that the cerebroprotective actions of chronically administered IB-MECA involve both neurons and glial cells, and indicate the possibility of distinct mechanisms that are affected in the course of chronic administration of the drug.

• Authors: D K Von Lubitz, R C Lin, M Boyd, N Bischofberger, K A Jacobson
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 367 Issue 2-3 Pg. 157-63 (Feb 19 1999) ISSN: 0014-2999 [Print] Netherlands
• PMID: 10078988 (Publication Type: Journal Article)

Chemical References

• Coloring Agents
• Glial Fibrillary Acidic Protein
• Microtubule-Associated Proteins
• Purinergic P1 Receptor Agonists
• Receptors, Purinergic P1
• N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine
• Nitric Oxide Synthase
• Adenosine

Topics

• Adenosine (administration & dosage, analogs & derivatives, pharmacology)
• Animals
• Brain Chemistry (drug effects)
• Carotid Arteries
• Coloring Agents
• Female
• Gerbillinae
• Glial Fibrillary Acidic Protein (drug effects, metabolism)
• Immunohistochemistry
• Ischemia (metabolism, pathology)
• Microtubule-Associated Proteins (drug effects, metabolism)
• Nitric Oxide Synthase (drug effects, metabolism)
• Purinergic P1 Receptor Agonists
• Receptors, Purinergic P1 (administration & dosage)
• Time Factors